|
Tuesday, March 08, 2005
BEVERLY, Mass., March 8, 2005 – Inotek Pharmaceuticals Corporation announced today that it has commenced enrollment in a Phase 1b trial for its lead compound, INO-1001, in patients with Glioblastoma Multiforme. This study will evaluate tolerability, safety, and pharmacokinetics. This study will also assess pharmacodynamics, including the ability for INO-1001 to transverse the blood brain barrier and to inhibit poly(ADP ribose) polymerase in Glioblastoma Multiforme tumors.
Please download PDF for full press release
#################################################
About Inotek Pharmaceuticals
Inotek Pharmaceuticals Corporation is a private, high-growth, development-stage pharmaceutical company that has leveraged its small molecule chemistry expertise to discover and develop a deep pipeline of therapeutics targeting cell death, DNA repair and inflammatory pathways. Inotek’s lead program is focused on blocking the nuclear DNA repair enzyme poly (ADP- ribose) polymerase (or PARP) that has broad application in a variety of unmet medical needs.
Inotek has one product in Phase 2a clinical development, one product in Phase 1b clinical development and four other products in various stages of pre-clinical development, targeting oncology, cardiovascular, and inflammatory disease. The Company is pursuing indications in hospital-based critical care markets as well as certain specialty care markets. Inotek currently has approximately 130 employees, located in its corporate headquarters and main research laboratories in Beverly, Massachusetts and its two operational sites in Israel.
 Download PDF
» Return to InotekCorp.com Press Room
| 
